Abstract
Background: The use of oral glucose tolerance test (OGTT) in evaluating biochemical control in acromegalic patients on somatostatin analogues (SSA) has recently been questioned. Aim: To gain further insights into this topic, we analyzed basal and nadir GH levels during OGTT in acromegalic patients on SSA. Subjects and methods: Basal IGF-I and GH values, as well as GH levels along the test, were analyzed in 115 standard OGTT performed in 33 acromegalic patients followed up between 1993 and 2009. All patients were on SSA at the time of the study; 22 of them had previously undergone unsuccessful surgery. No patient had undergone radiotherapy. GH suppression was considered normal when the hormonal value fell to <1 µg/l during OGTT. Diagnostic accuracy was analyzed by receiver operating characteristic (ROC) curves. Results: ROC analysis showed that the GH basal value yielding the best specificity (100%) was 3.9 µg/l. All patients with basal GH>3.9 µg/l displayed lack of GH suppression after OGTT and 80% also displayed high IGF-I. Conversely, patients with basal GH<3.9 µg/l presented a variable biochemical pattern with half of them failing to suppress GH after OGTT and 36.6% displaying high IGF-I levels. Conclusions: Our results show that baseline GH levels >3.9 µg/l are predictive of absent OGTT-dependent GH suppression; however, 20% of these patients display partial biochemical control (normal IGF-I levels). On the other hand, basal GH values <3.9 µg/l are not predictive of GH suppressibility by glucose and are often discordant with IGF-I levels.
Similar content being viewed by others
References
Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667–74.
Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a Consensus Statement. J Clin Endocrinol Metab 2000, 85: 526–9.
Melmed S, Casanueva F, Cavagnini F, et al. Consensus Statement: medical management of acromegaly. Eur J Endocrinol 2005, 153: 737–40.
Melmed S, Colao A, Barkan A, et al; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94: 1509–17.
Giustina A, Chanson P, Bronstein MD, et al; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95: 3141–8.
Machado EO, Taboada GF, Neto LV, et al. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 2008, 18: 389–93.
Resmini E, Barreca A, Ferone D, Giusti M, Sidoti M, Minuto F. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients. Clin Endocrinol (Oxf) 2005, 63: 294–7.
Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002, 87: 3142–7.
Cozzi R, Attanasio R, Grottoli S, et al. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? J Endocrinol Invest 2004, 27: 1040–7.
Alexopoulou O, Bex M, Abs R, T’Sjoen G, Velkeniers B, Maiter D. Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 2008, 93: 1324–30.
Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002, 87: 3537–42.
Trainer PJ. Editorial: acromegaly—consensus, what consensus? J Clin Endocrinol Metab 2002, 87: 3534–6.
Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998, 83: 3808–16.
Gullu S, Keles H, Delibasi T, Tonyukuk V, Kamel N, Erdogan G. Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol 2004, 150: 465–71.
Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 658–61.
Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004, 89: 495–500.
Jayasena CN, Wujanto C, Donaldson M, Todd JF, Meeran K. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients. Clin Endocrinol (Oxf) 2008, 68: 36–41.
Taboada GF, Correa LL, de Oliveira Machado E, et al. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR. Growth Horm IGF Res 2007, 17: 77–81.
Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009, 94: 523–7.
Sherlock M, Aragon Alonso A, Reulen RC, et al. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol (Oxf) 2009, 71: 74–81.
Colao A, Pivonello R, Cavallo LM, et al. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf) 2006, 65: 250–6.
Minuto F, Resmini E, Boschetti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf) 2004, 61: 138–44.
Arafat AM, Möhlig M, Weickert MO, et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in health controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 2008, 93: 1254–62.
Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009, 94: 1500–8.
Bianchi A, Giustina A, Cimino V, et al. Influence of growth hormone receptor d3 and full-lenght isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 2009, 94: 2015–22.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scacchi, M., Carzaniga, C., Vitale, G. et al. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I. J Endocrinol Invest 34, e291–e295 (2011). https://doi.org/10.3275/7802
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3275/7802